Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer-Reference-Cited by-同舟云学术

Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer

Published:2011-03 Issue:3 Volume:22 Page:588-594
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wildiers H.,Neven P.,Christiaens M.R.,Squifflet P.,Amant F.,Weltens C.,Smeets A.,van Limbergen E.,Debrock G.,Renard V.,Van Eenoo L.,Wynendaele W.,Paridaens R.

Funder

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/3/588/718170/mdq406.pdf

Reference34 articles.

1. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006;Kaufmann;Ann Oncol,2007

2. 4BA A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer – first results of the Austrian Breast and Colorectal Cancer Study Group-Trial 24 (ABCSG-24)

3. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27;Bear;J Clin Oncol,2006